Introduction:

[PDF] Supportive medications are used to protect specific cells or organs from the damaging side effects of cancer treatment. Protective medications are another name for supportive drugs. Allopurinol, Rasburicase, Amifostine, and Dexrazoxane are a few examples of medications that support cancer treatment.

Due to increased awareness of the negative effects of protracted cancer therapy, the market for drugs used in cancer supportive care has expanded significantly. The main reason driving the market's growth is the rise in the number of people experiencing cancer's signs and symptoms, including low blood counts, hair loss, vomiting, and nausea following treatment. Understanding which age groups of patients have higher demand for supportive pharmaceuticals attracts significant investment and ultimately will have a favorable impact on the growth of the Cancer Supportive Care Drugs Market

Increasing number of cancer patients worldwide

Due to factors like heavy tobacco use, workplace hazards, smoking, and many others, cancer is the world's top cause of death, accounting for close to ten million fatalities and twenty million active patients in 2020. The development of therapies and pharmaceuticals for cancer treatment is seeking greater investment by larger enterprises in order to aid in the expansion of the market for cancer treatment due to rising death toll and active patient statistics year over year.

Increasing investment in drugs related to cancer

The investment in innovative technology and drug formulations that assist therapy and after treatment has increased due to the incidence of cancer worldwide and the rise in death tolls. Major firms are entering the market through mergers and acquisitions in order to diversify their product offerings and accelerate market expansion. Government initiatives to establish new research facilities can increase the range of cancer-related medications available for use in post-treatment, including supporting medications, which will help the Cancer Supportive Drug Care market grow.

Restrains:

Due to some amount of side effects in Cancer Supportive drug that has been noticed, Introduction of new of targeted drug is nearly gaining popularity. Targeted frug therapy comes with lesser amount of side effects that are caused and are highly specific.

 

Cancer Supportive Care Drugs Market is segmented based on Therapeutic Class and Region.

Therapeutic Class Insight

On the basis of Therapeutic Class, Cancer Supportive Care Drugs Market is segmented G-CSFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis-Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Nonsteroidal Anti-Inflammatory Drug), And Other. Segmented G-CSFS (Granulocyte Colony Stimulating Factor) is expected to dominate the target market growth. G-CSFS due to their ability to reduce the risk of infection after cancer treatment.

Regional Insights:

On the basis of region, the Cancer Supportive Care Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia pacific region is expected to dominate the market with highest number of active patients and improvement in infrastructure can increase the chances of investment and product launch by key players leading to growth of Cancer Supportive Care Market Growth.

Report Scope:

Attribute	Details
Base year for estimation	2022
Forecast period	2022 – 2032
Market representation	Revenue in USD Billion & CAGR from 2022 to 2032
Market Segmentation	By Therapeutic Class- G-CSFS (Granulocyte Colony Stimulating Factor), ESAS (Erythropoiesis-Stimulating Agents), Antiemetics, Bisphosphonates, Opioids, NSAIDS (Nonsteroidal Anti-Inflammatory Drug), And Other.
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Cancer Supportive Care Drugs Market report based on Therapeutic Class and Region:

Cancer Supportive Care Drugs Market, By Therapeutic Class:

• G-CSFS (Granulocyte Colony Stimulating Factor),
• ESAS (Erythropoiesis-Stimulating Agents),
• Antiemetics,
• Bisphosphonates,
• Opioids,
• NSAIDS (Nonsteroidal Anti-Inflammatory Drug),
• And Other.

Cancer Supportive Care Drugs Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating the Cancer Supportive Care Drugs Market includes, Johnson & Johnson, Novartis AG, F.Hoffmann La-Roche Ltd., Amgen, Inc., Baxter International, Inc., Teva Pharmaceutical Industries Ltd., Acacia Pharma Ltd., Merck and Co., Inc., Helsinn Healthcare SA, and Heron Therapeutics.

• Johnson & Johnson *
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Novartis AG
•  F.Hoffmann
• La-Roche Ltd.
• Amgen, Inc.
• Baxter International, Inc.
•  Teva Pharmaceutical Industries Ltd.
•  Acacia Pharma Ltd.
•  Merck and Co., Inc.
•  Helsinn Healthcare SA
•   Heron Therapeutics.

“*” marked represents similar segmentation in other categories in the respective section.

Recent Development:

• In June 2021, The Food and Drug Administration (FDA) granted a primary review for a New Drug Application (NDA) to fruquintinib for patients with previously treated metastatic colorectal cancer, according to Takeda and HUTCHMED, the pharmaceutical companies manufacturing the drug.
• In Feb 2023, SOPHiA GENETICS, a cloud-native software company in the healthcare space, today announced that Synergy Oncology, part of Synergy Laboratories, a full-service diagnostic laboratory based in Mobile, Alabama, will use SOPHiA DDM™ to develop a new cancer profiling solution. The combination of technology from Synergy Oncology and SOPHiA GENETICS will expand Synergy’s oncology portfolio while helping to further the U.S. oncology market.
• In January 2023, Mark Cuban Cost Plus Drug Company and OncoPower Team Up to Bring Medication Adherence and Cost Savings to Cancer Patients, to build on OncoPower’s cancer care support with the launch of a Medication Savings Suite, which leverages Cost Plus Drugs competitive pricing on generic medication to seamlessly allow the cancer patients that use OncoPower to look up pricing and order less expensive medications.

Research Objective and Assumption

• Preface
• Research Objectives
• Study Scope
• Years Considered for the study
• Assumptions
• Abbreviations

Research Methodology

• Research data
• Primary Data
  • Primary Interviews
  • Primary Breakdown
  • Key data from Primary Sources
  • Key Thickness Insights
• Secondary Data
  • Major Secondary Sources
  • Secondary Sources
• Market Estimation
• Top-Down Approach
  • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
• Bottom-Up Approach
  • Approach for estimating market share by Bottom-up Analysis (Demand Side)
• Market Breakdown and Data Triangulation
• Research Assumptions

Market Preview

• Executive Summary
• Key Findings—Global Outlook for medical carts Strategies
  • Key Questions this Study will Answer
  • Market Snippet,    By Therapeutic Class
  • Market Snippet, By Region
• Opportunity Map Analysis
• Executive Summary—3 Big Predictions

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restrains
  • Market Opportunities
  • Market Trends
• DR Impact Analysis
• PEST Analysis
• Porter’s Five Forces Analysis
• Opportunity Orbit
• Market Investment Feasibility Index
• Macroeconomic Factor Analysis

Market Segmentation, By Therapeutic Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• G-CSFS (Granulocyte Colony Stimulating Factor
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• ESAS (Erythropoiesis-Stimulating Agents)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Antiemetics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Bisphosphonates
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Opioids
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• NSAIDS (Nonsteroidal Anti-Inflammatory Drug
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Other
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Global Market, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn),    By Therapeutic Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S.
    • Canada
• Europe
  • Market Size and Forecast (US$ Bn),    By Therapeutic Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • France
    • Germany
    • Russia
    • Italy
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast (US$ Bn),    By Therapeutic Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast (US$ Bn),    By Therapeutic Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• Brazil
• Mexico
• Rest of Latin America

• Middle East & Africa
  • Market Size and Forecast (US$ Bn),    By Therapeutic Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

Competitive Landscape

• Heat Map Analysis
• Market Presence and Specificity Analysis

Company Profiles

• Johnson & Johnson
  • Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
•  Novartis AG
  • Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• F.Hoffmann La-Roche Ltd
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• Amgen, Inc
  • Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• Baxter International, Inc
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• Teva Pharmaceutical Industries Ltd
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
•  Acacia Pharma Ltd.
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
•  Merck and Co., Inc
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• Helsinn Healthcare SA
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies
• Heron Therapeutics.
  •  Company Overview
  • Technology Portfolio
  • Key Highlights
  • Financial PerTechnologyance
  • Business Strategies

The Last Word

• Future Impact
• About Us
• Contact